Healthcare Industry News:  botulinum neurotoxin 

Devices Drug Delivery Urology Venture Capital

 News Release - February 7, 2022

Vensica Closes $19 Million Round with Investment from Strategic Partner Merz

TEL AVIV, Israel, Feb. 7, 2022 -- (Healthcare Sales & Marketing Network) -- Vensica Therapeutics ("Vensica"), a clinical stage biopharmaceutical company, has closed a $19 million investment round. Vensica executed a strategic collaboration agreement with Merz Therapeutics in 2021 and the Merz Group is participating in Vensica's financing with up to $3 million, bringing the total round to up to $19 million. The round was led by Israel Biotech Fund (IBF) with the participation of Laborie, Lew Pell, Agriline, and The Trendlines Group.

Merz Therapeutics, a business of the Merz Group, is a leader in the field of neurotoxins. Vensica has exclusively licensed Merz's botulinum neurotoxin A (Xeomin®) for needle-free use in urological procedures.

Vensica is unlocking the potential of neurotoxins in urology by developing minimally invasive solutions using the unique properties of therapeutic ultrasound to deliver botulinum toxin A to the bladder. Vensica's needle-free drug delivery platform is intended for the treatment of urological indications including overactive bladder, neurogenic bladder, and interstitial cystitis. Today's gold standard treatment requires needle injections of the neurotoxin into the bladder wall. Vensica's needle-free platform is expected to enable a far superior patient experience resolving needle-associated issues including pain, and urinary retention, making a generally more complicated procedure easier. Vensica's platform is anticipated to facilitate more efficacious treatment through more uniform delivery of the neurotoxin to the bladder wall.

The funds raised will support the company's phase II multicenter clinical trials in Europe and the USA. Vensica is expanding its workforce in Israel for next stage clinical and regulatory development of its device together with Merz Therapeutics' XEOMIN®, focusing on overactive bladder treatment.

Vensica CEO Avner Geva, commented, "This investment demonstrates Merz's commitment to us as a company and to establishing a urology treatment platform to treat bladder indications. Merz is the second strategic global company joining this round, following Laborie, a global urology company, that has made two investments in Vensica."

"Our ambition is to grow and to expand our product portfolio with more solutions that help us to create better outcomes for more patients," states Stefan Brinkmann, CEO of Merz Therapeutics. "Merz' commitment to Vensica reflects how promising the needless treatment of patients with overactive bladder is in combination with our strategic product XEOMIN®. The first months of our collaboration with Vensica already showed good progress and our further investment will strengthen our position as a strategic partner of Vensica and a driver for the development of a less invasive treatment of bladder diseases."

About Vensica Therapeutics

Vensica is an Israeli-based urology therapeutics company. The company is developing a unique platform for drug delivery for several urinary bladder indications, based on a proprietary ultrasound-assisted drug delivery system. The company was founded in 2015 by Avner Geva, (Yale, B.Sc, Technion, M.Sc) and is led and backed by medical and therapeutics leaders, including Chairman M.D., Ph.D, Nissim Darvish, Michael Ingber, M.D., board member appointed by IBF, Lew Pell, Laborie, Merz Pharmaceuticals, The Trendlines Group (SGX: 42T) (OTCQX: TRNLY), and The Israel Innovation Authority.

About Merz Therapeutics

Merz Therapeutics GmbH is dedicated to improving the lives of patients around the world. With its relentless research, development, and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurological conditions, liver disease, and other health conditions that severely impact patients' quality of life. Merz Therapeutics is headquartered in Frankfurt am Main, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Therapeutics GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated more than 110 years to developing innovations that serve unmet patient and customer needs.

Please visit

About Merz

Merz Group is a global, diversified company with its headquarters in Frankfurt, Germany. Its commitment to innovation, long-term perspective, and focus on profitable growth depict the privately owned company that has been around for more than 110 years. Merz Group has the businesses Merz Aesthetics, Merz Therapeutics, Merz Consumer Care, Merz Real Estate and Financial Investments. The company employs 3,969 people in 28 countries worldwide. To learn more, please visit

Source: Vensica Therapeutics

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.